In an analysis of 30 families affected by spinal muscular atrophy (SMA) we have used the solid-phase minisequencing method to determine the ratio between the number of telomeric and centromeric copies of the survival motor neuron gene (SMN and c BCD541 respectively) on normal and SMA chromosomes. This has enabled us to establish haplotypes with regard to SMN and c BCD541, and estimate their frequencies, on both types of chromosomes. Six predominant haplotypes were identified, three for normal chromosomes and three for SMA chromosomes, characterized by having 0, 1, or 2 copies, respectively, of c BCD541. We found evidence for the presence of patients homozygous for a deletion of SMN and with only one copy of c BCD541, but found none deleted for all copies of this gene. Several asymptomatic carriers of SMA with only a single copy of SMN and no copy of c BCD541 were identified. We could not confirm the hypothesis that the presence of more copies of c BCD541 is correlated to a less severe course of the disease. The frequencies of haplotypes characterized by having 0, 1, or 2 copies, respectively, of c BCD541 were found to differ significantly between normal and SMA chromosomes. This distribution can be explained by an underrepresentation of the haplotype completely lacking SMN genes, which is expected to cause early embryonic death in homozygotes. This first report of a direct haplotype analysis of SMN and c BCD541 should help clarify the role of c BCD541 in the pathogenesis of SMA.
INTRODUCTION
Spinal muscular atrophy (SMA) is one of the most common autosomal recessive disorders affecting 1 in 10 000 live births. It is classified into SMA type I (Werdnig-Hoffmann disease) with an onset in utero or in very early infancy, SMA type II with a less severe course, and SMA type III (Kugelberg-Welander disease) with onset in late childhood and with a better prognosis (1) . The three subtypes map to a single locus at 5q13 (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) , and recently two candidate genes have been cloned from this region: the survival motor neuron gene (12) and the neuronal apoptosis inhibitory protein gene (13) . The former gene is present in two almost identical versions, a centromeric ( c BCD541) and a telomeric (SMN) form, and >90% of SMA patients are allegedly homozygous for a deletion of at least exons 7 and 8 of SMN (12, (14) (15) (16) . A minority of cases shows absence of exon 7 but retention of exon 8, having a chimeric gene c BCD541/SMN, which is believed to be caused by a gene conversion-like event/unequal crossing-over between SMN and c BCD54 (17, 18) . The intact copy of the neuronal apoptosis inhibitory protein gene (NAIP) is deleted in ∼40% of patients with SMA type I and in a smaller proportion of patients with SMA II and III (16) . The difference of only 5 bp substitutions between SMN and c BCD541 (12, 19) can be used to distinguish between presence or absence of these genes. Detection of the deletion of SMN exons 7 and 8, either by single strand conformation analysis (SSCA) (12) or by restriction enzyme analysis (18) , is a rather simple task, and is used for both pre-and postnatal diagnosis of SMA.
Five percent of control samples are homozygous for deletion of c BCD54, an observation not made in SMA patients (12) . Both genes are transcribed, and since the expression of an alternate transcript of c BCD541 is increased in patients lacking SMN, it has been suggested that the copy number of c BCD541 influences the manifestation of the disease (12, 21, 22) . Up to 4 or 5 copies of c BCD541 have been reported in parents of SMA patients (21) , and unaffected sibs homozygous for the SMN deletion have been identified (21, 23, 24) . The relative importance of c BCD541 is therefore not established. Here we describe an approach to quantify, by solid-phase minisequencing (25) in combination with offspring analysis, the ratio between the number of telomeric and centromeric survival motor neuron genes in SMA families in *To whom correspondence should be addressed which the probands were found deleted for at least exons 7 and 8 ( Fig. 1) . We present evidence to suggest that as many as two copies of the c BCD541 gene may be present on a single chromosome. Consequently, three haplotypes (labelled A0, A1, and A2) with one copy of SMN and with 0, 1, or 2 copies of c BCD541, respectively, may be observed in normal individuals, and three haplotypes (labelled B0, B1, and B2) with a deletion of SMN and with 0, 1, or 2 copies of c BCD541, respectively, may be seen in SMA patients. We have determined the frequencies of these haplotypes among normal as well as SMA chromosomes in 30 SMA families, where at least one patient and one healthy sib were available for analysis.
RESULTS

Molecular diagnosis
Of the 30 families with known deletion of SMN exons 7 and 8, 5/13 SMA I, 14/15 SMA II and 2/2 SMA III patients had at least one copy of NAIP.
Solid-phase minisequencing
Standard curve. In order to test the reliability of the method we established a standard curve based on known ratios of amplification products of genomic DNA from a patient homozygous for the SMN deletion and from a normal individual homozygous for deletion of c BCD541. We found a linear relationship between the ratio R of 3 H-dCMP/ 3 H-dTMP incorporation and the gene ratio SMN/ c BCD541 within the range of 0.25 to 2 (Fig. 2) .
Haplotypes. Since up to at least two copies of c BCD541 per chromosome have been reported in SMA parents (21), we assumed, as our working hypothesis, that each normal control chromosome had one copy of intact SMN and 0, 1, or 2 copies of c BCD541, giving rise to three normal haplotypes, labelled A0, A1, and A2, respectively. By selecting only families in which the patients were homozygous for a deletion of exons 7 and 8 of the SMN, we inferred that the parents were heterozygous for the same deletion. Three different SMA haplotypes (B0, B1, and B2) would then be possible.
Controls.
We determined the R value in 34 individuals with no family history of SMA. The results fell into two groups with no overlap: R = 1 (0.84-1.18) and 2 (1.75-2.29), respectively. Using the values from Figure 3 the distribution of genotypes could be deduced (Table 1) . Nineteen controls had a ratio of 1, consistent with the genotypes A1A1 or A2A0. Fourteen other controls had a ratio of 2, consistent with the genotype A1A0. One person consistently had a C/T ratio of 3, which we believe could be the result of a gene conversion (not included in Table 1) .
We did not observe other values, indicating that the genotypes A1A2, A2A2 or A0A0 are quite rare. This further suggests that A1A1 is the most likely non-SMA genotype with an R value of 1. Table 1 . R values of controls and SMA carriers (parents) and their inferred genotypes (cf. SMA families. We determined R in 30 different SMA families (13 type I, 15 type II, and 2 type III) where at least one patient and one healthy sib were available for analysis. DNA from a total of 30 patients, 60 parents, 33 sibs, and seven grandparents was analysed. By using the information from all family members, i.e., including the offspring analyses involving healthy sibs, the haplotypes with respect to SMN and c BCD541 of both parents, the healthy sib, and the patient were deduced. Some illustrative pedigrees are shown in Figure 4 . In family 1, it is known from the microsatellite analysis that the healthy child is a carrier, having inherited the normal chromosome from his father and the SMA chromosome from his mother. The mother has an R value >>10 and therefore has no c BCD541 copies at all (A0,B0). The carrier child has an R value of 0.89, consistent with one SMN copy and one c BCD541 copy. Since he has inherited the SMA chromosome from his mother with null copies of either SMN or c BCD541 (B0), he must have received both the SMN and the c BCD541 copy from his father (A1). The father has an R value of 0.29, most likely having one copy of SMN and three copies of c BCD541.
From the haplotype of the carrier son, we can conclude that the fathers SMA chromosome has two c BCD541 copies (B2). From the inferred haplotypes in 30 families, we calculated the frequencies of the six different haplotypes among the SMA parents ( Table 2 ). The frequencies of the haplotypes A0, A1, and A2 were significantly different from those of the SMA haplotypes B0, B1, and B2 (p <0.01, χ 2 = 9.45; d.f. = 2). (19) found no evidence for additional copies of c BCD541 in either controls or in patients lacking the SMN exons 7 and 8. In accordance with these results and our preliminary data, we propose a model in which we assume the existence of both normal (A0, A1, and A2) and SMA chromosomes (B0, B1, and B2) with 0, 1, or 2 copies of c BCD541 respectively. Since several diploid genotypes in the model have identical R values, i.e., ratio between the number of SMN and c BCD541 copies as determined by minisequencing, an offspring analysis involving at least one healthy child is required to establish the parents' haplotypes.This was done by microsatellite marker analysis and only families in which this was possible were included in the present investigation. This has allowed us to determine the haplotypes of both normal and SMA chromosomes in the family members (Table 2 and 3) . We did not find any indication of a de novo mutation of either c BCD541 or SMN, neither did we encounter healthy asymptomatic carriers homozygously deleted for SMN. Patients lacking c BCD541 (genotype B0B0) were not found at all. The genotype with one copy of c BCD541 (B0B1) was found in all phenotypic classes of SMA: SMA I (2/13), SMA II (1/15), and SMA III (1/2). Patients with two copies of c BCD541 (B1B1 and B0B2) were found with equal frequency among SMA I (11/13) and SMA II (10/15), whereas the genotype with three copies of c BCD541 (B1B2) was found in SMA II (4/15) and SMA III (1/2). Overall there was no observed difference in c BCD541 copy number among the phenotypic classes of SMA, but we are aware of the small number of patients. The results indicate that the c BCD541 copy number does not substantially affect the course of the disease. The frequencies of normal and SMA chromosomes with 0, 1, or 2 copies of c BCD541 were found to differ significantly, reflecting a lack of the B0B0 genotype (no c BCD541) among patients with SMA (Table 2 ). Homozygosity for deletion of both SMN and c BCD541 is likely to cause early embryonic death, in which case families with both parents heterozygous for the B0 haplotype will escape detection. The normal haplotype A2 represents only 3% of all normal haplotypes, whereas the SMA haplotype B2 represents 13% of SMA haplotypes. The haplotypes with two copies of c BCD541 (A2 and B2) are probably caused by unequal crossing-over. The reciprocal event resulting in a chromosome with two copies of SMN should in theory be expected. However, the haplotype A2 is rare (3%) and B2 represents 13% of SMA chromosomes, which have a frequency 1:100. Chromosomes with two copies of SMN are therefore rare. Our hypothesis is based on the existence of three non-SMA haplotypes (A0, A1 and A2), and three SMA haplotypes (B0, B1 and B2), with one or null copies of SMN, respectively. Our results are in complete accordance with this. However, due to the relatively small number of families we cannot rule out that chromosomes with more than one SMN copy exist.
In seven out of 58 parents we found an R value consistent with a SMN/ c BCD541 ratio of 1:3 (0.27-0.36). From the offspring analysis we concluded that the genotypes of the parents were either A1B2 (five parents) or A2B1 (two parents). However, the distinction between values of 0.25 and 0.33 is difficult, and the possibility that chromosomes with three c BCD541 copies do exist cannot be ruled out.
A gene conversion, changing the T in c BCD541 into a C will cause the c BCD541 to be erroneously counted as SMN. We believe that the single control individual we found with a repeated R value of 3.0 represents an example of such a gene conversion, although the presence of three copies of SMN could be an alternative explanation.
The most common non-SMA haplotype is A1. This was also confirmed by analysing normal controls. 19/35 showed an R value consistent with the genotype A1A1 or A2A0. We found a frequency of the A0 haplotype of 0.3, giving an expected frequency of A0A0 individuals (homozygously deleted for c BCD541) of 0.09. This figure is in agreement with the reported frequency of 5-10%, which is based on dosage measurements in SSCP experiments (12) .
The minisequencing method is not directly suited for carrier diagnosis as such since normal controls and carriers may give the same R values (Table 1) . However, R values of 0.33 or 0.25 are carrier-specific, and a ratio of 0.5 is only expected to be present in 0.1% (0.03*0.03) of non-carrier controls (genotype A2A2) (cf. Fig. 3 and Table 2 ).
Both SMN and c BCD541 are transcribed (12, 27) , and the expression of an alternatively spliced c BCD541 transcript is increased in SMA patients compared to controls (12) . However, it is not known whether two copies of c BCD541 in cis-position will both be transcribed. If this is not the case, patients with the genotype B0B2 will be phenotypically similar to B0B1 patients. Our identification of two asymptomatic parents with the genotype A0B0 (one copy of SMN and no copy of c BCD541) indicates that a c BCD541 transcript is not necessary in all situations.
Asymptomatic carriers, parents as well as sibs, homozygous for the SMN deletion have been identified by several groups. Explanations such as quantitative or qualitative alterations of the c BCD541, a possible third SMN homologue, or gene conversions have been proposed, but no experimental support of any of the hypotheses has been presented.
We have suggested the existence of six different haplotypes, with respect to the copy numbers of SMN and c BCD541. We found no patients without c BCD541; patients with a single copy of c BCD541 were found in all classes of SMA. Based on a still rather small sample, our results thus indicate that the c BCD541 copy number does not substantively affect the phenotypic severity of the disease course. The influence of NAIP on the severity of the disease is supported in this material. Among the SMAI patients 9/13 were deleted for NAIP, whereas only 1/15 SMAII and 0/2 SMAIII showed a deletion of NAIP.
In the present study we selected SMA families with a deletion of both exons 7 and 8, in which gene conversion-like events are not expected. Since the method is based on only one base pair difference between the two genes, interpretation of the results would be much more difficult in non-deletion families.
MATERIALS AND METHODS
SMA families
Families were selected in which (a) the proband was homozygous for a deletion of both exons 7 and 8 of SMN and (b) at least one healthy sib was available for analysis. A total of 30 families were studied: in 13 the patients were classified as SMA I, in 15 as SMA II, and in two as SMA III.
PCR analyses for SMN exons 7 and 8, and NAIP exons 5 and 13
SMN exons 7 and 8 were amplified with the primers described by van der Steege et al. (20) , and digested with DraI (exon 7) and DdeI (exon 8).
Multiplex PCR of NAIP exons 5 and 13 was performed as described by Roy et al. (13) and the PCR products analysed by electrophoresis through 1.5% agarose gels followed by ethidium bromide staining.
Microsatellite analysis
All family members were typed for the microsatellite marker (D5S435) proximal to the SMA locus and for the distal markers D5S112 (MAP5 and MAP3) (7) . One primer in each set was 5′-labelled with FITC (fluorescein-isothiocyanate). The PCR products were analysed on an A.L.F. DNA sequencer, using the Fragment Manager software (Pharmacia).
Solid-phase minisequencing
The solid-phase minisequencing method was performed as described by Syvänen (25) . This method allows determination of the ratio between two DNA sequences present as a mixture in a sample and differing from each other only in a single nucleotide position. SMN and c BCD541 differ at one base pair in exon 7: SMN has a C whereas c BCD541 has a T in position 873 of the non-template strand. A DNA segment of 204 bp spanning this part of exon 7 was amplified from genomic DNA using 0.5 µmol/l of the non-biotinylated (R111) primer and 0.2 µmol/l of the 5′-biotinylated primer (541C770) (12) . The biotinylated PCR products were diluted 5 times in 20 mmol/l Na-phosphate buffer (pH 7.5) containing 0.15 mol/l NaCl and 1 g/l Tween 20. 50 µl of the diluted product were captured, in duplicate, in streptavidincoated microtiter wells for 1.5 h at 37_C. The wells were washed 5 times in 40 mmol/Tris-HCl (pH 8.8), 1 mmol/l EDTA, 50 mmol/l NaCl and 1 g/l Tween 20, using an automatic plate washer. The product was denatured by adding 100 µl l50 mmol/l NaOH and washed as above. 50 µl of a minisequencing solution containing 0.2 µmol/l of the detection primer (5′-CTTTATTTTC-CTTACAGGGTTT-3′, complementary to the sequence immediately preceding the nucleotide in question), 0.1 µC i of either 3 H-dCTP (SMN) or 3 H-dTTP ( c BCD541), and 0.05 U Taq polymerase in PCR buffer was added to the wells and incubated for 15 min at 50_C. The wells were washed as above. The primer was then released by adding of 100 µl of 50mmol/l NaOH and the amount of radioactivity (c.p.m.) incorporated into the primer was measured. After correction for differences in specific activity of the two dNTPs, the ratio (R) between incorporated 3 H-dCMP and 3 H-dTMP will define the ratio between SMN and c BCD541 in the sample. All determinations were done in duplicate or triplicate with a variation in the R values of 10%.
